Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 12, 2013, Pages 1136-1151

  Rege, Sanil ^a,b,c   Hodgkinson, Suzanne J ^d,e  

^a PENINSULA HEALTH   (Australia)

^b Positive Psychology Wellness Centre   (Australia)

^c Psych Scene ^*  (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e LIVERPOOL HOSPITAL   (Australia)

Author keywords

Anti NMDA encephalitis; autoimmunity; bipolar disorder; cytokines; Hashimoto's encephalopathy; immune dysregulation; microglia; neuroinflammation; neuropsychiatric systemic lupus erythematosus; oligodendrocytes

Indexed keywords

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BIPOLAR DISORDER; CELL DAMAGE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; ENCEPHALITIS; EXCITOTOXICITY; HASHIMOTO ENCEPHALOPATHY; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-NMDA ENCEPHALITIS; AUTOIMMUNITY; BIPOLAR DISORDER; CYTOKINES; HASHIMOTO'S ENCEPHALOPATHY; IMMUNE DYSREGULATION; MICROGLIA; NEUROINFLAMMATION; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; OLIGODENDROCYTES;

AUTOIMMUNITY; BIPOLAR DISORDER; BRAIN; HUMANS; IMMUNE SYSTEM;

EID: 84889049613     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413499077     Document Type: Review

References (179)

1. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. British Journal of Anaesthesia. 2000 ; 85: 129-135
2. Aerni A, Traber R, Hock C, et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. American Journal of Psychiatry. 2004 ; 161: 1488-1490
3. Alao AO, Chlebowski S, Chung C. Neuropsychiatric systemic lupus erythematosus presenting as bipolar I disorder with catatonic features. Psychosomatics. 2009 ; 50: 543-547
4. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunology Today. 2000 ; 21: 141-147
5. Andreazza AC, Kauer-Sant'Anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. Journal of Affective Disorders. 2008 ; 111: 135-144
6. Ankeny DP, Popovich PG. B cells and autoantibodies: complex roles in CNS injury. Trends in Immunology. 2010 ; 31: 332-338
7. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism. 2008 ; 58: 1130-1135
8. Arrojo M, Perez-Rodriguez MM, Mota M, et al. Psychiatric presentation of Hashimoto's encephalopathy. Psychosomatic Medicine. 2007 ; 69: 200-201
9. Bataller L, Kleopa KA, Wu GF, et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. Journal of Neurology, Neurosurgery and Psychiatry. 2007 ; 78: 381-385
10. Bellone M Autoimmune disease: pathogenesis. Hoboken, NJ: Wiley ; 2005:
11. Benes FM, Matzilevich D, Burke RE, et al. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Molecular Psychiatry. 2006 ; 11: 241-251
12. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews. 2011 ; 35: 804-817
13. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends in Immunology. 2010 ; 31: 24-31
14. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience. 2007 ; 8: 57-69
15. Bochetta A, Tamburini G, Cavolina P, et al. Affective psychosis, Hashimoto's thyroiditis, and brain perfusion abnormalities: case report. Clinical Practice and Epidemiology in Mental Health. 2007 ; 3: 31
16. Boufidou F, Nikolaou C, Alevizos B, et al. Cytokine production in bipolar affective disorder patients under lithium treatment. Journal of Affective Disorders. 2004 ; 82: 309-313
17. Boutros NN, Torello M, McGlashan TH. Electrophysiological aberrations in borderline personality disorder: state of the evidence. Journal of Neuropsychiatry and Clinical Neurosciences. 2003 ; 15: 145-154
18. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathologica. 2010 ; 119: 37-53
19. Breunis MN, Kupka RW, Nolen WA, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biological Psychiatry. 2003 ; 53: 157-165
20. Brietzke E, Kapczinski F. TNF-α as a molecular target in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 ; 32: 1355-1361
21. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, et al. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain, Behavior and Immunity. 2009 ; 23: 1079-1082
22. Brietzke E, Stabellini R, Grassis-Oliveira R, et al. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectrums. 2011 ; 16: 157-168
23. Canelo-Aybar C, Loja-Oropeza D, Cuadra-Urteaga J, et al. Hashimoto's encephalopathy presenting with neurocognitive symptoms: a case report. Journal of Medical Case Reports. 2011 ; 4: 337
24. Capuron L, Pagnoni G, Demetrashvili M, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biological Psychiatry. 2005 ; 58: 190-196
25. Capuron L, Pagnoni G, Demetrashvili MF, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology. 2007 ; 32: 2384-2392
26. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Archives of Neurology. 2006 ; 63: 197-202
27. Chang CC, Shiah IS, Chen CL, et al. Bipolar disorder induced by resuming interferon-alpha treatment in a patient with chronic hepatitis B. Journal of Medical Sciences. 2005 ; 25: 101-104
28. Chastain EM, Miller SD. Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunological Reviews. 2012 ; 245: 227-238
29. Chiba Y, Katsuse O, Takahashi Y, et al. Anti-glutamate receptor Ïμ2 antibodies in psychiatric patients with anti-thyroid autoantibodies - a prevalence study in Japan. Neuroscience Letters. 2012 ; 534: 217-222
30. Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. International Journal of Developmental Neuroscience. 2011 ; 29: 311-324
31. Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proceedings of the National Academy of Sciences, USA. 2012 ; 109: 5995-5999
32. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alpha therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Journal of Clinical Psychiatry. 2005 ; 66: 1050-1057
33. Corcione A, Aloisi F, Serafini B, et al. B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmunity Reviews. 2005 ; 4: 549-554
34. Daban C, Vieta E, Mackin P, et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatric Clinics of North America. 2005 ; 28: 469-480
35. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology. 2008 ; 7: 1091-1098
36. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology. 2011 ; 10: 63-74
37. Dantzer R, Konsman JP, Bluthé RM, et al. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?. Autonomic Neuroscience. 2000 ; 85: 60-65
38. Das S, Basu A. Inflammation: a new candidate in modulating adult neurogenesis. Journal of Neuroscience Research. 2007 ; 86: 1199-1208
39. Davison K. Autoimmunity in psychiatry. British Journal of Psychiatry. 2012 ; 200: 353-355
40. DeGiorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine. 2001 ; 7: 1189-1193
41. Dickerson F, Stallings C, Vaughan C, et al. Antibodies to the glutamate receptor in mania. Bipolar Disorders. 2012 ; 14: 547-553
42. do Prado CH, Rizzo LB, Wieck A, et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology. 2012 ; 38: 667-676
43. Drexhage RC, Hoogenboezem TH, Versnel MA, et al. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain, Behavior and immunity. 2011 ; 25: 1206-1213
44. Dugan LL, Sensi SL, Canzoniero LM, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. Journal of Neuroscience. 1995 ; 15: 6377-6388
45. Dunn AJ. Cytokine activation of the HPA axis. Annals of the New York Academy of Sciences. 2000 ; 917: 608-617
46. Eaton WW, Pedersen MG, Nielsen PR, et al. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disorders. 2010 ; 12: 638-646
47. Edgar N, Sibille E. A putative functional role for oligodendrocytes in mood regulation. Translational psychiatry. 2012 ; 2: e109
48. Fairweather D Autoimmune disease: mechanisms. Hoboken, NJ: Wiley ; 2007:
49. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Review of Neurotherapeutics. 2007 ; 7: 789-796
50. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996 ; 272: 50-53
51. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis and Rheumatism. 2007 ; 56: 1242-1250
52. Geracioti TD, Kling MA, Post RM, et al. Antithyroid antibody-linked symptoms in borderline personality disorder. Endocrine. 2003 ; 21: 153-158
53. Gidron Y, Kupper N, Kwaijtaal M, et al. Vagus-brain communication in atherosclerosis-related inflammation: a neuroimmunomodulation perspective of CAD. Atherosclerosis. 2007 ; 195: e1 - e9
54. Gigante AD, Bond DJ, Lafer B, et al. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disorders. 2012 ; 14: 478-487
55. Gómez-Bernal GJ, Reboreda A, Romero F, et al. A case of Hashimoto's encephalopathy manifesting as psychosis. Primary Care Companion to the Journal of Clinical Psychiatry. 2007 ; 9: 318-319
56. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell. 2007 ; 130: 25-35
57. Gorman M. Will anti-neuronal antibody biomarkers make neuropsychiatric systemic lupus erythematosus no longer a diagnosis of exclusion?. Developmental Medicine and Child Neurology. 2011 ; 53: 483
58. Goverman J. Autoimmune T cell responses in the central nervous system. Nature Reviews Immunology. 2009 ; 9: 393-407
59. Haggerty JJ, Evans DL, Golden RN, et al. The presence of antithyroid antibodies in patients with affective and nonaffective psychiatric disorders. Biological Psychiatry. 1990 ; 27: 51-60
60. Haggerty JJ, Silva SG, Marquardt M, et al. Prevalence of antithyroid antibodies in mood disorders. Depression and Anxiety. 1997 ; 5: 91-96
61. Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. Journal of Rheumatology. 2006 ; 33: 1873-1877
62. Harley JB. The genetic etiology of systemic lupus erythematosus: a short dispatch from the combat zone. Genes and Immunity. 2002 ; 3: S1-4
63. Harris MG, Fabry Z. Initiation and regulation of CNS autoimmunity: balancing immune surveillance and inflammation in the CNS. Neuroscience and Medicine. 2012 ; 3: 203-224
64. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry. 2007 ; 62: 1310-1316
65. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Practice and Research. Clinical Rheumatology. 2002 ; 16: 229-244
66. Hillegers MH, Reichart CG, Wals M, et al. Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents. European Neuropsychopharmacology. 2007 ; 17: 394-399
67. Hu S, Peterson PK, Chao CC. Cytokine-mediated neuronal apoptosis. Neurochemistry International. 1997 ; 30: 427-431
68. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annual Review of Neuroscience. 2001 ; 24: 677-736
69. Hughes GRV. Is it lupus? The St. Thomas' Hospital "alternative" criteria. Clinical and Experimental Rheumatology. 1998 ; 16: 250-252
70. Iancu I, Sverdlik A, Dannon PN, et al. Bipolar disorder associated with interferon-alpha treatment. Postgraduate Medical Journal. 1997 ; 73: 834
71. Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009 ; 460: 748-752
72. Issa G, Wilson C, Terry AV, et al. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiology of Disease. 2010 ; 39: 327-333
73. Johansson V, Nybom R, Wetterberg L, et al. Microscopic particles in two fractions of fresh cerebrospinal fluid in twins with schizophrenia or bipolar disorder and in healthy controls. PLoS One. 2012 ; 7: e45994
74. Jonsen A, Bengtsson AA, Sturfelt G, et al. Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Research and Therapy. 2004 ; 6: R557 - R562
75. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007 ; 69: 644-654
76. Kahl KG, Bens S, Ziegler K, et al. Cortisol, the cortisol- dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biological Psychiatry. 2006 ; 59: 667-671
77. Kaindl AM, Degos V, Peineau S, et al. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Annals of Neurology. 2012 ; 72: 536-549
78. Kapadia M, Sakic B. Autoimmune and inflammatory mechanisms of CNS damage. Progress in Neurobiology. 2011 ; 95: 301-333
79. Kapczinski F, Dias VV, Frey BN, et al. Brain-derived neurotrophic factor in bipolar disorder: beyond trait and state: comment on "Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders". Bipolar Disorders. 2009 ; 11: 221-222
80. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it. Molecular Psychiatry. 2012 ; 17: 1174-1179
81. Karassa FB, Ioannidis JP, Touloumi G, et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM: Monthly Journal of the Association of Physicians. 2000 ; 93: 169-174
82. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology. 2009 ; 12: 447-458
83. Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. Journal of Neuropsychiatry and Clinical Neurosciences. 2011 ; 23: 90-97
84. Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic disorders. American Journal of Psychiatry. 2010 ; 167: 1039-1050
85. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders. 2007 ; 104: 91-95
86. Konradi C, Sillivan SE, Clay HB. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiology of Disease. 2012 ; 45: 37-47
87. Knight JG, Menkes DB, Highton J, et al. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Molecular Psychiatry. 2007 ; 12: 424-431
88. Krishnadas R, Cavanagh J. Depression: an inflammatory illness?. Journal of Neurology, Neurosurgery and Psychiatry. 2012 ; 83: 495-502
89. Kupka RW, Nolen WA, Post RM, et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biological Psychiatry. 2002 ; 51: 305-311
90. La Cava A. Natural Tregs and autoimmunity. Frontiers in Bioscience. 2009 ; 14: 333
91. La Cava A, Matarese G. The weight of leptin in immunity. Nature Reviews Immunology. 2004 ; 4: 371-379
92. Lampron A, ElAli A, Rivest S. Innate immunity in the CNS: redefining the relationship between the CNS and its environment. Neuron. 2013 ; 78: 214-232
93. Langan C, McDonald C. Neurobiological trait abnormalities in bipolar disorder. Molecular Psychiatry. 2009 ; 14: 833-846
94. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neuroscience Letters. 2009 ; 466: 139-143
95. Liu CY, Tseng MC, Lin PH. Encephalopathy associated with autoimmune thyroid disease (Hashimoto's thyroiditis) presenting as depression: a case report. General Hospital Psychiatry. 2011a ; 33: 641.e647 - e649
96. Liu W, Tang Y, Feng J. Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sciences. 2011b ; 89: 141-146
97. López-Armada MJ, Riveiro-Naveira RR, Vaamonde-García C, et al. Mitochondrial dysfunction and the inflammatory response. Mitochondrion. 2013 ; 13: 106-118
98. Losif RE, Ekdahl CT, Ahlenius H, et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. Journal of Neuroscience. 2006 ; 26: 9703-9712
99. Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Translational Neurodegeneration. 2012 ; 1: 1-13
100. Maat P, Graaff E, Beveren NM, et al. Psychiatric phenomena as initial manifestation of encephalitis by anti-NMDA receptor antibodies. Acta Neuropsychiatrica. 2012 ;:
101. McIntosh AM, Maniega SM, Lymer GKS, et al. White matter tractography in bipolar disorder and schizophrenia. Biological Psychiatry. 2008 ; 64: 1088-1092
102. McKernan DP, Dennison U, Gaszner G, et al. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Translational Psychiatry. 2011 ; 1: e36
103. Maes M, Delange J, Ranjan R, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Research. 1997 ; 66: 1-11
104. Maes M, Fišar Z, Medina M, et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates - Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012a ; 20: 127-150
105. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica. 2007 ; 89: 346-351
106. Maes M, Mihaylova I, Kubera M, et al. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. Journal of Affective Disorders. 2011 ; 135: 414-418
107. Maes M, Ringel K, Kubera M, et al. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. Journal of Affective Disorders. 2012b ; 136: 386-392
108. Mahon K, Burdick KE, Szeszko PR. A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neuroscience and Biobehavioral Reviews. 2010 ; 34: 533-554
109. Mak A, Ho RCM, Lau CS. Clinical implications of neuropsychiatric systemic lupus erythematosus. Advances in Psychiatric Treatment. 2009 ; 15: 451-458
110. Malek-Ahmadi P. Mood disorders associated with interferon treatment: theoretical and practical considerations. Annals of Pharmacotherapy. 2001 ; 35: 489-495
111. Manji HK, Moore GJ, Rajkowska G, et al. Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry. 2000 ; 5: 578-593
112. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nature Reviews Immunology. 2006 ; 6: 823-835
113. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Annals of Neurology. 2006 ; 59: 880-892
114. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry. 2009 ; 65: 732-741
115. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Advances in Experimental Medicine and Biology. 1999 ; 461: 107-116
116. Miller CL, Llenos IC, Dulay JR, et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Research. 2006 ; 1073: 25-37
117. Mocellin R, Walterfang M, Velakoulis D. Hashimotos encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007 ; 21: 799-811
118. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003 ; 302: 1760-1765
119. Monov S, Monova D. Classification criteria for neuropsychiatric systemic lupus erythematosus: do they need a discussion?. Hippokratia. 2008 ; 12: 103-107
120. Moscavitch SD, Szyper-Kravitz M, Shoenfeld Y. Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship. Clinical Immunology. 2009 ; 130: 235-243
121. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today. 1996 ; 17: 138-146
122. Mössner R, Heils A, Stöber G, et al. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochemistry International. 1998 ; 33: 251-254
123. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. Journal of Affective Disorders. 2013 ; 144: 16-27
124. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurologic Clinics. 2010 ; 28: 61-73
125. Mussig K, Bartels M, Gallwitz B, et al. Hashimoto's encephalopathy presenting with bipolar affective disorder. Bipolar Disorders. 2005 ; 7: 292-297
126. Najjar S, Pearlman DM, Alper K, et al. Neuroinflammation and psychiatric illness. Journal of Neuroinflammation. 2013 ; 10: 43
127. NeuweltCMYoungRG (2009) Managing neuropsychiatric lupus: top 10 clinical pearls. Clinical judgment and experience must prevail. Available at: www.musculoskeletalnetwork.com/display/article/1145622/1396901 (consulted January 2013).
128. Ng PC, Li K, Wong RP, et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2003 ; 88: F209-213
129. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nature Reviews Neuroscience. 2002 ; 3: 216-227
130. O'Brien SM, Scully P, Scott LV, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. Journal of Affective Disorders. 2006 ; 90: 263-267
131. Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. Journal of Biomedicine and Biotechnology. 2010 ; 2010: 268436
132. Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. European Journal of Neurology. 2005 ; 12: 392-398
133. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disorders. 2007 ; 9: 596-602
134. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nature Reviews Immunology. 2002 ; 2: 37-45
135. Pacheco R, Gallart T, Lluis C, et al. Role of glutamate on T-cell mediated immunity. Journal of Neuroimmunology. 2007 ; 185: 9-19
136. Padmos RC, Bekris L, Knijff EM, et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biological Psychiatry. 2004 ; 56: 476-482
137. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Archives of General Psychiatry. 2008 ; 65: 395-407
138. Padmos RC, Van Baal GCM, Vonk R, et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Archives of General Psychiatry. 2009 ; 66: 957
139. Petri M, Naqibuddin M, Carson KA, et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. Journal of Rheumatology. 2008 ; 35: 2348-2354
140. Plotnikoff NP Cytokines: stress and immunity. Boca Raton, FL: CRC Press ; 2007:
141. Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Current Neuropharmacology. 2011 ; 9: 449-457
142. Rao JS, Harry GJ, Rapoport SI, et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Molecular Psychiatry. 2010 ; 15: 384-392
143. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. Journal of Clinical Investigation. 2012 ; 122: 1164-1171
144. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Archives of Internal Medicine. 1987 ; 147: 1577-1580
145. Rohleder N, Wolf JM, Kirschbaum C, et al. Effects of cortisol on emotional but not on neutral memory are correlated with peripheral glucocorticoid sensitivity of inflammatory cytokine production. International Journal of Psychophysiology. 2009 ; 72: 74-80
146. Rosenfeld MR, Dalmau J. Anti-NMDA-receptor encephalitis and other synaptic autoimmune disorders. Current Treatment Options in Neurology. 2011 ; 13: 324-332
147. Rossi B, Angiari S, Zenaro E, et al. Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. Journal of Leukocyte Biology. 2011 ; 89: 539-556
148. Santer DM, Yoshio T, Minota S, et al. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. Journal of Immunology. 2009 ; 182: 1192-1201
149. Schroeter ML, Sacher J, Steiner J, et al. Serum S100B represents a new biomarker for mood disorders. Current Drug Targets. 2013 ;:
150. Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin. 2004 ; 130: 601-630
151. Shalev H, Serlin Y, Friedman A. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovascular Psychiatry and Neurology. 2009 ; 2009: 278531
152. Sidhom O, Laadhar L, Zitouni M, et al. Spectrum of autoantibodies in Tunisian psychiatric inpatients. Immunological Investigations. 2012 ; 41: 538-549
153. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?. Pharmacological Reviews. 2010 ; 62: 199-236
154. Soczynska JK, Kennedy SH, Goldstein BI, et al. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. Neurotoxicology. 2009 ; 30: 497-521
155. Soderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1 beta in bipolar disorder. Journal of Psychiatry and Neuroscience. 2011 ; 36: 114-118
156. Spivak B, Radwan M, Bartur P, et al. Antinuclear autoantibodies in relation to bipolar affective disorder and lithium therapy. European Psychiatry. 1996 ; 11: 50-52
157. Squassina A, Costa M, Congiu D, et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacological Research. 2013 ; 73C: 1-7
158. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Current Opinion in Immunology. 2007 ; 19: 281-286
159. Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmunity Reviews. 2008 ; 7: 209-213
160. Stout SC, Nemeroff CB. Stress and psychiatric disorders. Seminars in Neuroscience. 1994 ; 6: 271-280
161. Tedla Y, Shibre T, Ali O, et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiopian Medical Journal. 2011 ; 49: 211
162. Thomas AJ, Davis S, Ferrier IN, et al. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biological Psychiatry. 2004 ; 55: 652-655
163. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 ; 367: 29-35
164. Valles SL, Blanco AM, Pascual M, et al. Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathology. 2004 ; 14: 365-371
165. Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1β enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. Journal of Neuroscience. 2003 ; 23: 8692-8700
166. Vonk R, van der Schot AC, Kahn RS, et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder?. Biological Psychiatry. 2007 ; 62: 135-140
167. Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Human Psychopharmacology: Clinical and Experimental. 2002 ; 17: 175-179
168. Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. International Journal of Inflammation. 2012 ; 2012: 819467
169. Wallace DJ, Hahn BH Dubois' lupus erythematosus. Philadelphia, PA: Lippincott Williams and Wilkins ; 2006:
170. Webster MJ, O'Grady J, Kleinman JE, et al. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience. 2005 ; 133: 453-61
171. Wright MT. Neuropsychiatric illness in systemic lupus erythematosus: insights from a patient with erotomania and Geschwind's syndrome. American Journal of Psychiatry. 2010 ; 167: 502-507
172. Yeh HM, Hu SY. Mania as an initial feature of systemic lupus erythematosus: a case report. Journal of Internal Medicine of Taiwan. 2007 ; 18: 283-286
173. Yu HH, Lee JH, Wang LC, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus. 2006 ; 15: 651-657
174. Zanetti MV, Jackowski MP, Versace A, et al. State-dependent microstructural white matter changes in bipolar I depression. European Archives of Psychiatry and Clinical Neuroscience. 2009 ; 259: 316-328
175. Zhang B, Angelidou A, Alysandratos KD, et al. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation. 2010 ; 7: 80
176. Zhu CB, Carneiro AM, Dostmann WR, et al. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. Journal of Biological Chemistry. 2005 ; 280: 15649-15658
177. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008 ; 112: 1557-1569
178. Zotova E, Nicoll JA, Kalaria R, et al. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Research and Therapy. 2010 ; 2: 1
179. Zou J, Wang YX, Dou FF, et al. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochemistry International. 2010 ; 56: 577-584